185 related articles for article (PubMed ID: 35283386)
1. Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor.
Konta Y; Saito E; Sato K; Furuta K; Miyauchi K; Furukawa A; Sato H; Yamamoto T
Intern Med; 2022 Nov; 61(21):3239-3243. PubMed ID: 35283386
[TBL] [Abstract][Full Text] [Related]
2. Author's reply: Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis.
Konta Y; Saito E; Sato K; Furuta K; Miyauchi K; Furukawa A; Sato H; Yamamoto T
Intern Med; 2023 Mar; 62(5):819. PubMed ID: 35871589
[No Abstract] [Full Text] [Related]
3. Detailed Causality between Sodium-glucose Cotransporter 2 Inhibitor and Tubulointerstitial Nephritis.
Morita H; Kakeshita K; Imamura T
Intern Med; 2023 Mar; 62(5):817. PubMed ID: 35871584
[No Abstract] [Full Text] [Related]
4. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
6. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Nadkarni GN; Ferrandino R; Chang A; Surapaneni A; Chauhan K; Poojary P; Saha A; Ferket B; Grams ME; Coca SG
Diabetes Care; 2017 Nov; 40(11):1479-1485. PubMed ID: 28827404
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.
van Bommel EJM; Muskiet MHA; Tonneijck L; Kramer MHH; Nieuwdorp M; van Raalte DH
Clin J Am Soc Nephrol; 2017 Apr; 12(4):700-710. PubMed ID: 28254770
[TBL] [Abstract][Full Text] [Related]
8. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors.
Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E
Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129
[TBL] [Abstract][Full Text] [Related]
9. Rare allergic reaction of the kidney: sitagliptin-induced acute tubulointerstitial nephritis.
Alsaad AA; Dhannoon SM; Pantin SA; Porter IE
BMJ Case Rep; 2016 Jul; 2016():. PubMed ID: 27436034
[TBL] [Abstract][Full Text] [Related]
10. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
11. Acute tubulointerstitial nephritis following treatment with exenatide.
Nandakoban H; Furlong TJ; Flack JR
Diabet Med; 2013 Jan; 30(1):123-5. PubMed ID: 22762797
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice.
Lin B; Koibuchi N; Hasegawa Y; Sueta D; Toyama K; Uekawa K; Ma M; Nakagawa T; Kusaka H; Kim-Mitsuyama S
Cardiovasc Diabetol; 2014 Oct; 13():148. PubMed ID: 25344694
[TBL] [Abstract][Full Text] [Related]
14. Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity.
Saly DL; Perazella MA
Am J Physiol Renal Physiol; 2017 Oct; 313(4):F951-F954. PubMed ID: 28637789
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
16. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
Menne J; Dumann E; Haller H; Schmidt BMW
PLoS Med; 2019 Dec; 16(12):e1002983. PubMed ID: 31815931
[TBL] [Abstract][Full Text] [Related]
17. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
[TBL] [Abstract][Full Text] [Related]
18. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
Carlson CJ; Santamarina ML
Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
[TBL] [Abstract][Full Text] [Related]
19. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.
Iskander C; Cherney DZ; Clemens KK; Dixon SN; Harel Z; Jeyakumar N; McArthur E; Muanda FT; Parikh CR; Paterson JM; Tangri N; Udell JA; Wald R; Garg AX
CMAJ; 2020 Apr; 192(14):E351-E360. PubMed ID: 32392523
[TBL] [Abstract][Full Text] [Related]
20. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
